With its large population, one-child policy and increasing emphasis on preventative care, China is poised for a vaccine boom. The catalyst for growth may come from the expected modernization of the country’s massive national immunization program.
BEIJING – China’s vaccine segment took off in 2007 when the government doubled its national vaccination program coverage to 14 vaccines, and the segment has maintained 15% annual growth.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.
Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.
CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.
Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.
